Concord Biotech Limited (NSE:CONCORDBIO)
1,238.50
+72.30 (6.20%)
Jun 3, 2026, 12:41 PM IST
Concord Biotech Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 135.79 | 9.05 | 151.42 | 34.99 | 6.67 |
Short-Term Investments | 4,021 | 179.89 | 228.22 | 305.8 | 872.5 |
Trading Asset Securities | - | 3,165 | 2,437 | 1,369 | 734.73 |
Cash & Short-Term Investments | 4,156 | 3,354 | 2,817 | 1,710 | 1,614 |
Cash Growth | 23.91% | 19.09% | 64.71% | 5.96% | -19.76% |
Accounts Receivable | 4,602 | 5,217 | 3,496 | 2,738 | 2,322 |
Other Receivables | - | 210.46 | 193.66 | 217.95 | 272.74 |
Receivables | 4,602 | 5,427 | 3,690 | 2,956 | 2,594 |
Inventory | 3,264 | 2,397 | 2,080 | 2,123 | 1,951 |
Prepaid Expenses | - | 73.91 | 73.31 | 55.19 | 47.61 |
Other Current Assets | 479.16 | 100.48 | 303.06 | 433.05 | 119.5 |
Total Current Assets | 12,501 | 11,352 | 8,962 | 7,277 | 6,327 |
Property, Plant & Equipment | 8,661 | 8,442 | 7,865 | 7,655 | 6,436 |
Long-Term Investments | 885.83 | 227.81 | 20.7 | 79.25 | 2.56 |
Goodwill | 3.96 | - | - | - | - |
Other Intangible Assets | 14.25 | 11.22 | 3.2 | 1.98 | 35.77 |
Long-Term Deferred Tax Assets | 29.37 | - | - | - | - |
Other Long-Term Assets | 252.18 | 308.86 | 156.1 | 126.8 | 327.4 |
Total Assets | 22,347 | 20,343 | 17,007 | 15,140 | 13,128 |
Accounts Payable | 1,019 | 1,130 | 944.35 | 938 | 831.06 |
Accrued Expenses | - | 192.07 | 168.21 | 146.19 | 131.45 |
Short-Term Debt | - | 3.81 | - | - | 43.37 |
Current Portion of Long-Term Debt | - | - | 62.3 | 250 | 250 |
Current Portion of Leases | 8.82 | 19.58 | 16.21 | 1.47 | 15.96 |
Current Income Taxes Payable | 0.09 | 101.27 | 54.94 | 89.99 | - |
Current Unearned Revenue | - | - | - | 13.13 | 32.72 |
Other Current Liabilities | 662.76 | 393.5 | 175.55 | 479.67 | 247.1 |
Total Current Liabilities | 1,691 | 1,841 | 1,422 | 1,918 | 1,552 |
Long-Term Debt | - | - | - | 62.36 | 312.49 |
Long-Term Leases | 14.33 | 6.3 | 18.87 | 1.64 | 3.11 |
Long-Term Deferred Tax Liabilities | 453.59 | 340.22 | 280.65 | 234.39 | 209.71 |
Other Long-Term Liabilities | 37.2 | 28.2 | 19.56 | 22.97 | 18.74 |
Total Liabilities | 2,196 | 2,215 | 1,741 | 2,240 | 2,096 |
Common Stock | 104.62 | 104.62 | 104.62 | 104.62 | 95.11 |
Additional Paid-In Capital | - | 819.71 | 819.71 | 819.71 | 829.22 |
Retained Earnings | - | 17,203 | 14,342 | 11,976 | 10,108 |
Comprehensive Income & Other | 20,066 | - | - | - | - |
Total Common Equity | 20,171 | 18,127 | 15,266 | 12,900 | 11,032 |
Minority Interest | -19.23 | - | - | - | - |
Shareholders' Equity | 20,151 | 18,127 | 15,266 | 12,900 | 11,032 |
Total Liabilities & Equity | 22,347 | 20,343 | 17,007 | 15,140 | 13,128 |
Total Debt | 23.16 | 29.69 | 97.38 | 315.46 | 624.93 |
Net Cash (Debt) | 4,133 | 3,325 | 2,719 | 1,395 | 988.98 |
Net Cash Growth | 24.32% | 22.26% | 94.98% | 41.02% | -11.58% |
Net Cash Per Share | 39.26 | 31.78 | 25.99 | 13.33 | 9.45 |
Filing Date Shares Outstanding | 104.77 | 104.62 | 104.62 | 104.62 | 104.62 |
Total Common Shares Outstanding | 104.77 | 104.62 | 104.62 | 104.62 | 104.62 |
Working Capital | 10,810 | 9,512 | 7,541 | 5,359 | 4,775 |
Book Value Per Share | 192.53 | 173.27 | 145.93 | 123.31 | 105.45 |
Tangible Book Value | 20,152 | 18,116 | 15,263 | 12,898 | 10,996 |
Tangible Book Value Per Share | 192.35 | 173.17 | 145.90 | 123.29 | 105.11 |
Land | - | 629.93 | 547.11 | 547.11 | 547.11 |
Buildings | - | 3,553 | 2,576 | 2,463 | 2,226 |
Machinery | - | 6,622 | 4,979 | 4,788 | 4,285 |
Construction In Progress | - | 501.31 | 2,115 | 1,727 | 741.55 |